Remarkably, ablation of Ccl19+ FRCs in the lung substantially increases the tumor burden in xenograft models of lung cancer in immunized mice, underscoring the critical role of these cells for sustaining robust anti-cancer immune responses and slowing lung cancer progression (Fig. 1).1 This evidence concerns the gene CCL19 and lung cancer.